Companion Diagnostic in Development for Glioblastoma Multiforme Patients
|
By LabMedica International staff writers Posted on 10 Feb 2010 |
|
A companion diagnostic test kit is being developed for an immunotherapy vaccine for the treatment of glioblastoma multiforme (GBM).
The vaccine is called PF-04948568 (CDX-110), and is currently in Phase 2 clinical development for the treatment of newly diagnosed GBM.
Pfizer Inc. (New York, NY, USA) and DxS (Manchester, UK), a wholly owned subsidiary of Qiagen (QIA; Frankfurt, Germany), have entered into an agreement to develop the companion diagnostic test kit. In 2008, Pfizer received an exclusive worldwide licence to PF-04948568 (CDX-110) from Celldex Therapeutics Inc. (Needham, MA, USA).
The investigational drug PF-04948568 (CDX-110) is a peptide vaccine which targets the tumor-specific epidermal growth factor receptor variant III (EGFRvIII), a mutated form of the epidermal growth factor receptor that is only present in cancer cells and occurs in 25-40 % of GBM tumors. The Qiagen assay is designed to identify patients, whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment.
The EGFRvIII companion diagnostic will be developed and manufactured at Qiagen's DxS unit. The diagnostic will be a real-time polymerase chain reaction (R-T PCR) assay used to detect EGFRvIII RNA in tumor tissue. The assay will offer a simple workflow, supporting its clinical utility in routine mutation testing.
Pfizer Oncology is committed to the discovery, investigation, and development of treatment options to improve the outlook for cancer patients worldwide.
Qiagen is a global provider of sample and assay technologies. The company's products include one of the broadest panels of molecular diagnostic tests for prevention, profiling, and personalized healthcare available worldwide.
Related Links:
Pfizer Inc.
DxS
Qiagen
Celldex Therapeutics
The vaccine is called PF-04948568 (CDX-110), and is currently in Phase 2 clinical development for the treatment of newly diagnosed GBM.
Pfizer Inc. (New York, NY, USA) and DxS (Manchester, UK), a wholly owned subsidiary of Qiagen (QIA; Frankfurt, Germany), have entered into an agreement to develop the companion diagnostic test kit. In 2008, Pfizer received an exclusive worldwide licence to PF-04948568 (CDX-110) from Celldex Therapeutics Inc. (Needham, MA, USA).
The investigational drug PF-04948568 (CDX-110) is a peptide vaccine which targets the tumor-specific epidermal growth factor receptor variant III (EGFRvIII), a mutated form of the epidermal growth factor receptor that is only present in cancer cells and occurs in 25-40 % of GBM tumors. The Qiagen assay is designed to identify patients, whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalized treatment.
The EGFRvIII companion diagnostic will be developed and manufactured at Qiagen's DxS unit. The diagnostic will be a real-time polymerase chain reaction (R-T PCR) assay used to detect EGFRvIII RNA in tumor tissue. The assay will offer a simple workflow, supporting its clinical utility in routine mutation testing.
Pfizer Oncology is committed to the discovery, investigation, and development of treatment options to improve the outlook for cancer patients worldwide.
Qiagen is a global provider of sample and assay technologies. The company's products include one of the broadest panels of molecular diagnostic tests for prevention, profiling, and personalized healthcare available worldwide.
Related Links:
Pfizer Inc.
DxS
Qiagen
Celldex Therapeutics
Gold Member
Aspiration System
VACUSAFE
HPV Test
Allplex HPV28 Detection
Clinical Informatics Platform
CLARION™
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
